, Volume 31, Issue 6, pp 483–485 | Cite as

The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities

  • Paolo MartellettiEmail author


Migraine is among the highest impact illnesses in the global population. Its negative ramifications are personal, social, economic and work related. Research on the development of new preventative migraine therapies has been idle for decades. The introduction, shortly, of an innovative pharmacological class useful for migraine prevention, namely monoclonal antibodies towards calcitonin gene-related peptide or its receptor, opens a new, immense therapeutic scenario. The necessity to manage the chronic and refractory forms of migraine must not take our attention away from the target of the pre-chronic forms. This is the most important target in every study. Indeed, by reducing the evolution towards chronic and consequently refractory chronic migraine, we will reduce complications caused by pharmacological abuse, the serious disability of these devastating chronic states, and the healthcare expenses needed to manage chronicity, abuse and consequent pathologies. We will, lastly, be able to rehabilitate these patients to achieve a quality working and social life, and facilitate their reintegration into daily normality.


Compliance with Ethical Standards


No funding was received for the preparation of this manuscript.

Conflicts of interest

Paolo Martelletti has received fees for participation on advisory boards from Teva, Allergan, Amgen, Novartis, and Electrocore; educational grants from Allergan, ACRAF, and Pfizer; royalties from Springer; research grants from Elytra Pharma, and Sanofi; travel reimbursement from EFIC, EHF and Springer Nature; and an editorial grant from Springer Nature.


  1. 1.
    Edvinsson L. The journey to establish CGRP as a migraine target: a retrospective view. Headache. 2015;55:1249–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Erdling A, Sheykhzade M, Edvinsson L. Differential inhibitory response to telcagepant on αCGRP induced vasorelaxation and intracellular Ca2+ levels in the perfused and non-perfused isolated rat middle cerebral artery. J Headache Pain. 2017;18:61.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Steinberg A, Frederiksen SD, Blixt FW, Warfvinge K, Edvinsson L. Expression of messenger molecules and receptors in rat and human sphenopalatine ganglion indicating therapeutic targets. J Headache Pain. 2016;17:78.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11:1045–57.CrossRefPubMedGoogle Scholar
  5. 5.
    Hou M, Xing H, Cai Y, Li B, Wang X, Li P, Hu X, Chen J. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain. 2017;18:42.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Yuan H et al. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs 2017, in press, doi: 10.1007/s40259-017-0250-5.
  7. 7.
    Stovner LJ, Haimanot RT. Epidemiology of common headache disorders. In: Martelletti P, Steiner TJ, (eds) Handbook of headache. Milan Heidelberg Dordrecht London New York: Springer; 2011. pp. 17–25. SBN 978-88-470-2009-2. doi  10.1007/978-88-470-1700-9.
  8. 8.
    Negro A, Curto M, Lionetto L, Giamberardino MA, Martelletti P. Chronic migraine treatment: from OnabotulinumtoxinA onwards. Expert Rev Neurother. 2016;16:1217–27.CrossRefPubMedGoogle Scholar
  9. 9.
    Giamberardino MA, Mitsikostas DD, Martelletti P. Update on medication-overuse headache and its treatment. Curr Treat Options Neurol. 2015;17:368.CrossRefPubMedGoogle Scholar
  10. 10.
    Negro A, Curto M, Lionetto L, Guerzoni S, Pini LA, Martelletti P. A critical evaluation on MOH current treatments. Curr Treat Options Neurol. 2017;15(19):32.CrossRefGoogle Scholar
  11. 11.
    Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. J Headache Pain. 2015;16:58.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17:104.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A, Russell MB, Mitsikostas DD, Jensen RH. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014;28(15):47.CrossRefGoogle Scholar
  14. 14.
    Martelletti P, Giamberardino MA, Mitsikostas DD. Greater occipital nerve as target for refractory chronic headaches: from corticosteroid block to invasive neurostimulation and back. Expert Rev Neurother. 2016;16:865–6.CrossRefPubMedGoogle Scholar
  15. 15.
    MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37:779–88.CrossRefPubMedGoogle Scholar
  16. 16.
    Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017;18:34.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Martelletti P, Curto M. Headache: cluster headache treatment - RCTs versus real-world evidence. Nat Rev Neurol. 2016;12:557–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Clinical and Molecular MedicineSapienza UniversityRomeItaly
  2. 2.Regional Referral Headache Centre, Sant’Andrea HospitalRomeItaly

Personalised recommendations